Home Ingredients L-Phenylalanine / DLPA
Mood & Mental HealthCognitiveStress & Anxiety

L-Phenylalanine / DLPA

Evidence Level
Limited
2 Clinical Trials
5 Documented Benefits
2/5 Evidence Score

L-Phenylalanine is an essential aromatic amino acid and the precursor to tyrosine, dopamine, norepinephrine, epinephrine, and melanin. Found in meat, fish, dairy, soy, nuts, seeds. Sold supplementally as L-phenylalanine, D-phenylalanine, or DL-phenylalanine (DLPA — racemic mixture). Used for depression, ADHD, chronic pain, vitiligo, and as a catecholamine precursor. Critical contraindication: phenylketonuria (PKU) — must completely avoid phenylalanine.

Studied Dose L-phenylalanine: 500–1,500 mg/day for mood/cognitive support; DLPA: 375–2,250 mg/day for chronic pain; vitiligo: 50–100 mg/kg combined with UV therapy
Active Compound L-Phenylalanine, D-Phenylalanine, or DL-Phenylalanine (DLPA — racemic)

Benefits

Catecholamine Precursor (Mood Support)

L-Phenylalanine converts to L-tyrosine, then to L-DOPA, then to dopamine, norepinephrine, and epinephrine. Theoretical basis for mood and cognitive support — though clinical trials in depression have been mixed and small.

Supported by Trial 1, Trial 2

Chronic Pain (DLPA)

D-phenylalanine (in DLPA) inhibits enkephalinase — the enzyme that breaks down endogenous opioid peptides (enkephalins). Theoretical mechanism for chronic pain modulation. Clinical evidence remains limited; no large rigorous RCTs definitively support DLPA for chronic pain despite popular use.

Supported by Trial 1

Vitiligo Adjunct (with UV Therapy)

L-Phenylalanine + UVA or UVB therapy has been studied for vitiligo (pigment-loss skin condition). Modest repigmentation reported in some trials. Standard vitiligo care includes topical corticosteroids, calcineurin inhibitors, JAK inhibitors (ruxolitinib), and excimer laser.

Supported by Trial 2, Trial 1

ADHD Support (Limited Evidence)

Theoretical use as catecholamine precursor for ADHD. Small trials have been mixed. Standard ADHD pharmacotherapy (stimulants like methylphenidate, amphetamines) has vastly stronger evidence.

Supported by Trial 1, Trial 2

Appetite Modulation

Phenylalanine stimulates cholecystokinin (CCK) release — promoting satiety. Modest evidence; not established weight management therapy.

Supported by Trial 1, Trial 2

Mechanism of action

1

Catecholamine Synthesis Pathway

Phenylalanine → tyrosine (via phenylalanine hydroxylase + BH4 cofactor) → L-DOPA (via tyrosine hydroxylase) → dopamine → norepinephrine → epinephrine. Phenylalanine hydroxylase deficiency causes phenylketonuria (PKU).

2

Melanin Synthesis

Phenylalanine → tyrosine → L-DOPA → dopaquinone → melanin. Basis for vitiligo therapy theory.

3

Enkephalinase Inhibition (D-Phenylalanine)

D-phenylalanine (the unnatural isomer) inhibits enkephalinase — the enzyme that degrades endogenous enkephalins (opioid peptides). Theoretical analgesic mechanism. L-phenylalanine does not have this effect.

4

CCK Release

Phenylalanine in the small intestine stimulates CCK release from I cells — promoting satiety and gallbladder contraction.

Clinical trials

1
DLPA for Depression — Older Pilot Studies

Several small uncontrolled and pilot studies in 1970s-80s examining D-phenylalanine and DLPA for depression. (Beckmann et al. 1979 Arch Psychiatr Nervenkr; others)

Small depression pilots.

Modest signals reported, but trials were small, often uncontrolled, and used inconsistent methodology. Critical caveat: not replicated in modern rigorous RCTs. Standard depression care relies on SSRIs, SNRIs, atypical antidepressants, psychotherapy. DLPA remains alternative/CAM approach.

2
L-Phenylalanine + UVA for Vitiligo — Clinical Studies
PubMed

Several clinical studies examining oral L-phenylalanine + UVA exposure for vitiligo repigmentation. (Schulpis et al. 1989; Cormane et al. 1985; later studies)

Vitiligo patients.

Modest repigmentation reported in some trials, particularly with UVA exposure. Effect sizes variable. Standard vitiligo care has evolved — JAK inhibitors (topical ruxolitinib, FDA-approved 2022) represent significant advance.

Side effects and drug interactions

Common Potential side effects

Mild GI distress (nausea, heartburn) at higher doses.
Headache, anxiety, restlessness — particularly at high doses; reflects catecholamine elevation.
Insomnia if taken late in day — stimulating effect.
Increased blood pressure at high doses — caution with hypertension.

Important Drug interactions

MAOIs — DO not combine; phenylalanine is precursor to catecholamines; MAOIs prevent their breakdown; hypertensive crisis risk; contraindicated.
L-DOPA / Sinemet — phenylalanine competes with L-DOPA for blood-brain barrier transport via large neutral amino acid transporter; can reduce L-DOPA efficacy in Parkinson's.
Antipsychotics — theoretical antagonism via dopaminergic effects.
Stimulants (methylphenidate, amphetamines) — additive catecholamine effects; potential for hypertension or anxiety.
SSRIs/SNRIs — generally compatible but theoretical serotonin/catecholamine interactions; monitor.
Selegiline (low-dose MAO-B selective) — caution; same MAOI concern at higher doses.

More Mood & Mental Health Ingredients

Mood & Mental Health
Affron® (Standardized Saffron Extract)
Affron® (Pharmactive Biotech) is a standardized saffron stigma extract — Crocus sativus L.…
Mood & Mental Health
Saffron Extract (Crocus sativus)
Saffron is the dried stigmas of Crocus sativus — the most expensive spice in the world by…
Mood & Mental Health
Crocin & Crocetin
Crocin and crocetin are the carotenoid pigments responsible for saffron's deep red color.…
Mood & Mental Health
Vanizem® (Grains of Paradise Extract for Stress + Mood + Sleep — PLT Health)
Vanizem® is PLT Health Solutions' proprietary extract of Aframomum melegueta (Grains of Pa…

Explore Other Ingredients

Antioxidant
Setria® Glutathione
Setria® is Kyowa Hakko's patented reduced L-glutathione (GSH) produced via fermentation —…
Bone Health
Collagen
Collagen is the most abundant structural protein in the human body — making up roughly 30%…
Hair, Skin & Nails
Hyaluronic Acid
Hyaluronic acid is a naturally occurring substance in the body, primarily found in connect…

Frequently asked questions about L-Phenylalanine / DLPA

What is L-phenylalanine used for?

L-phenylalanine is an essential amino acid the body converts into tyrosine and then into dopamine and norepinephrine. It is used for mood, focus, and alertness, and a related form (DLPA) is used for discomfort support.

What is the difference between L-phenylalanine and DLPA?

L-phenylalanine is the natural form used for neurotransmitter support. DLPA (a mix of D- and L-forms) is often used for discomfort and mood, as the D-form may influence the body's natural discomfort-modulating compounds. They are used for somewhat different goals.

How much L-phenylalanine should I take?

Doses commonly range from about 500 mg to 1.5 grams, taken on an empty stomach. Follow product labeling, and use it earlier in the day given its stimulating, dopamine-related effects.

Who should avoid phenylalanine?

People with the genetic condition PKU (phenylketonuria) must strictly avoid phenylalanine. It should also be used cautiously with MAOI antidepressants and in pregnancy. Check with your doctor if any apply.

What is L-Phenylalanine / DLPA?

L-Phenylalanine is an essential aromatic amino acid and the precursor to tyrosine, dopamine, norepinephrine, epinephrine, and melanin. Found in meat, fish, dairy, soy, nuts, seeds. Sold supplementally as L-phenylalanine, D-phenylalanine, or DL-phenylalanine (DLPA — racemic mixture).

What is L-Phenylalanine / DLPA used for?

L-Phenylalanine / DLPA is researched primarily for Mood & Mental Health, Cognitive, and Stress & Anxiety. L-Phenylalanine converts to L-tyrosine, then to L-DOPA, then to dopamine, norepinephrine, and epinephrine. Theoretical basis for mood and cognitive support — though clinical trials in depression have been mixed and small.

What is the recommended dosage of L-Phenylalanine / DLPA?

The clinically studied dose is L-phenylalanine: 500–1,500 mg/day for mood/cognitive support; DLPA: 375–2,250 mg/day for chronic pain; vitiligo: 50–100 mg/kg combined with UV therapy Always follow the product label and check with a healthcare provider for personal advice.

Is L-Phenylalanine / DLPA safe, and does it have side effects?

For most healthy adults, L-Phenylalanine / DLPA is well tolerated at studied doses. Reported effects can include: Mild GI distress (nausea, heartburn) at higher doses. Headache, anxiety, restlessness — particularly at high doses; reflects catecholamine elevation. It may also interact with some medications. L-Phenylalanine / DLPA is not right for everyone, so check with a healthcare provider first if you are pregnant or breastfeeding, have a medical condition, or take prescription medication.

Does L-Phenylalanine / DLPA interact with any medications?

Possible interactions include: MAOIs — DO not combine; phenylalanine is precursor to catecholamines; MAOIs prevent their breakdown; hypertensive crisis risk; contraindicated. If you take prescription medication, check with a pharmacist or doctor before using it.

How strong is the scientific evidence for L-Phenylalanine / DLPA?

NutraSmarts rates the evidence for L-Phenylalanine / DLPA as Limited (2 out of 5). It is backed by 2 clinical trials and 3 cited references summarized on this page. A higher rating reflects more, larger, and better-designed human studies.

References(3 citations)

Evidence ratings on NutraSmarts are based on the totality of human clinical research, with emphasis on randomized controlled trials, meta-analyses, and systematic reviews. The references below directly support claims made throughout this page.

  1. Fernstrom JD, Fernstrom MH Tyrosine, phenylalanine, and catecholamine synthesis and function in the brain Journal of Nutrition. 2007;137(6 Suppl 1):1539S-1547S; discussion 1548S. doi: 10.1093/jn/137.6.1539S.PubMedUsed to support: Foundational review establishing that dietary phenylalanine is converted to tyrosine, which is the direct precursor for brain catecholamines (dopamine, norepinephrine, epinephrine); dietary protein intake influences catecholamine synthesis rates. Supports Catecholamine Precursor (Mood Support) benefit.
  2. Siddiqui AH, Stolk LM, Bhaggoe R, Hu R, Schutgens RB, Westerhof W L-phenylalanine and UVA irradiation in the treatment of vitiligo Dermatology. 1994;188(3):215-218. doi: 10.1159/000247142.PubMedUsed to support: Open trial (n=149) and double-blind trial (n=32) showing oral L-phenylalanine combined with UVA produced repigmentation up to 77% in the open trial and 60% in the blinded trial in vitiligo patients. Supports Vitiligo Adjunct (with UV Therapy) benefit.
  3. Antoniou C, Schulpis H, Michas T, Katsambas A, Frajis N, Tsagaraki S, Stratigos J Vitiligo therapy with oral and topical phenylalanine with UVA exposure International Journal of Dermatology. 1989;28(8):545-547. doi: 10.1111/j.1365-4362.1989.tb04613.x.PubMedUsed to support: Clinical trial comparing oral L-phenylalanine (100 mg/kg) + UVA vs. oral + topical 10% L-phenylalanine cream + UVA in vitiligo patients (n=21); best results seen with combination oral + topical approach, with no adverse reactions. Supports Vitiligo Adjunct (with UV Therapy) benefit.